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Background: Obesity is recognized as an independent predictor of coronary artery disease; however, its importance in
peripheral arterial disease is less clear. The aim of this study was to assess the association between obesity and the severity
and outcome of intermittent claudication.
Methods: This study was a prospective cohort study based at a tertiary referral center. Sixty patients with intermittent
claudication selected for conservative treatment were assessed for obesity and metabolic syndrome by using the International
Diabetes Federation definition. Other risk factors, including diabetes, hypertension, smoking history, serum lipids, adipocy-
tokines, andC-reactive protein, weremeasured by clinical and blood assessment.Obesity andmetabolic syndromewere related
to the severity of peripheral arterial disease, defined by ankle-brachial pressure index and graded treadmill measuredmaximum
walking distance (MWD) and initial claudication distance, by using multiple linear regression analysis allowing for traditional
atherosclerotic risk factors. Patients were followed up for 24 months, and combined outcome was reported in terms of death,
cardiovascular events, or requirement for revascularization. The effect of obesity and metabolic syndrome on outcome was
investigated by using Kaplan-Meier and Cox proportional hazard analysis.
Results: Obesity and serum adiponectin were independently associated with the severity of peripheral arterial disease
measured by ankle-brachial pressure index (P .03 and .001), initial claudication distance (P .009 and .03), andMWD
(P  .001 and .04). Metabolic syndrome was independently associated only with MWD (P  .02). By 24 months,
outcome events occurred in 37%  7% and 43%  9% of patients with metabolic syndrome or obesity, respectively,
compared with 0% and 11%  6% of those without these diagnoses. Waist circumference independently predicted the
likelihood of outcome events (relative risk, 1.16; 95% confidence interval, 1.08-1.26; P < .001).
Conclusions: These findings, if confirmed in other cohorts, suggest the importance of treating obesity in patients with
intermittent claudication. Serum adiponectin concentrations may be an important guide to the efficacy of treatment in
patients with intermittent claudication and obesity. ( J Vasc Surg 2007;45:40-6.)The increasing incidence of obesity has focused re-
search on this modifiable risk factor for cardiovascular
disease.1,2 There is particular interest in a constellation of
risk factors associated with obesity, known as the metabolic
syndrome, that are thought to result from insulin resis-
tance.3 Some, but not all, studies suggest an independent
association between obesity or metabolic syndrome and
coronary events.4-7 Because peripheral arterial disease is
common in patients with diabetes mellitus, it is not surpris-
ing that metabolic syndrome has been particularly linked
with lower limb artery disease.8,9 In animal models, obesity
has been specifically linked with impaired limb blood
flow.10 The interpretation of studies of obesity and meta-
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40bolic syndrome is complicated by the use of a number of
different definitions and evidence; depending on which
criteria are used, the outcome varies.4,11 Two large popu-
lation studies found no association between body mass
index and symptomatic or asymptomatic lower limb artery
disease.12,13 In one of these studies in which 708 men were
examined, a waist-hip ratio above the median was indepen-
dently associated with peripheral arterial disease at an odds
ratio of 1.7.13 These findings support studies of coronary
artery disease indicating that abdominal girth is a much
more important risk factor for vascular disease than body
mass index.4 It has been suggested that screening patients
with demonstrated vascular disease for obesity and meta-
bolic syndrome may identify high-risk subgroups to direct
intensive treatment.14 Few studies have examined the effect
of obesity and metabolic syndrome on the outcome in
patients with existing peripheral arterial disease. In this
study, we assessed the prevalence of metabolic syndrome
and obesity in a cohort of patients with intermittent clau-
dication. We used girth measurements and the Interna-
tional Diabetes Federation definition of metabolic syn-
drome.15 We assessed two hypotheses: (1) that obesity
and/or metabolic syndrome is associated with more severe
intermittent claudication and (2) that obesity and/or met-
abolic syndrome is associated with a poorer prognosis dur-
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 1 Golledge et al 41ing follow-up, as evidenced by more frequent cardiovascu-
lar or revascularization events.
METHODS
Patients. Approval for this study was provided by the
ethics committees of the Townsville Hospital, the Mater
Hospital, and James Cook University. In this prospective
study, we consecutively assessed patients with symptomatic
peripheral arterial disease referred to the Townsville Hos-
pital. Patients were initially assessed by a consultant vascular
surgeon to identify those with intermittent claudication
secondary to peripheral arterial disease. Intermittent clau-
dication was defined by an appropriate history, a positive
Edinburgh claudication questionnaire response, and an
ankle-brachial pressure index (ABPI) less than 0.9.16 Pa-
tients with critical ischemia (rest pain or tissue loss) or
nonvascular symptoms were excluded. Because only pa-
tients with lifestyle-limiting intermittent claudication are
referred to the vascular clinic, all patients underwent a
computed tomographic angiogram to assess whether endo-
vascular therapies were feasible. Because the second aim of
this study was to assess the association between obesity and
cardiovascular or revascularization events, patients selected
for endovascular or open vascular surgery were excluded.
The remaining patients who had intermittent claudication
and were selected for medical treatment were eligible for
the study. Medical treatment consisted of advice on exer-
cise, smoking cessation, and control of cardiovascular risk
factors under the supervision of a cardiovascular physician.
As a result, 10 and 6 patients were started on treatment for
diabetes and dyslipidemia, respectively. The patients had
detailed further assessment, including recording of medical
history, examination, blood, and imaging findings.
Clinical definitions. Hypertension was defined by
systolic blood pressure of 130 mm Hg or higher, diastolic
blood pressure of 85 mm Hg or higher, or previously
diagnosed and treated high blood pressure.15 Diabetes was
defined by a fasting blood glucose of 7.0mmol/L or higher
or, for patients with fasting glucose between 6.1 and 6.9
mmol/L, a positive oral glucose tolerance test.17 Cigarette
smoking classification was based on a history as current
smokers (smoked within the last month), ex-smokers
(given up for more than 1 month), and never-smokers.
Ischemic heart disease was defined by a history of myocar-
dial infarction, angina, or coronary revascularization. Cere-
brovascular disease was defined by a history of stroke,
transient ischemic attack, or cerebral revascularization.
Dyslipidemia was defined according to the European Joint
Society of Cardiologists criteria as total cholesterol of 4.5
mmol/L or higher, low-density lipoprotein 2.5 mmol/L
or higher, or current lipid-lowering treatment.18
Blood analysis. Blood was collected after an over-
night fast and assessed for full blood count, urea and
electrolytes, glucose, cholesterol, triglycerides, high-
density lipoprotein (HDL), low-density lipoprotein, and
C-reactive protein (CRP), as previously described.19
Blood glucose was measured by the glucose oxidase
method, lipids by automated enzymatic methods, and CRPby particle-enhanced turbidimetry (Roche Diagnostics,
Basel, Switzerland).19 Serum was stored at 80°C for later
batch assessment of adiponectin, leptin, and resistin con-
centrations by using enzyme-linked immunosorbent assay
(R&D Systems). Intra-assay and interassay coefficients of
variation for these assays are between 3% and 6% in our
laboratory.
Assessment of obesity and metabolic syndrome.
On entry into the study, patients’ weight, height, and waist
and hip circumference were measured in accordance with
guidelines of the International Society for the Advance-
ment of Kinanthropometry.20 The percentage body fat was
measured by bioelectrical impedance scales (TBF 521;
Tanita Corporation of America, Arlington Heights, Ill).21
Body mass index was calculated as weight in kilograms
divided by height in meters squared. Obesity and metabolic
syndrome were defined by using the International Diabetes
Federation classification, which uses varying waist circumfer-
ences for different populations. In our study, because patients
were of European origin, we defined obesity as awaist circum-
ference of 94 cm or greater for men and 80 cm or greater in
women.15 Metabolic syndrome was diagnosed when obesity
was present in addition to two of the following: fasting trig-
lycerides 1.7 mmol/L or more or specific treatment to de-
crease triglycerides; HDL less than 1.03 mmol/L in men or
less than 1.29 mmol/L in women or specific treatment to
increase HDL; hypertension; fasting glucose 5.6 mmol/L or
more; or treated diabetes mellitus.15
Objective assessment of peripheral vascular disease.
A consultant vascular surgeon documented the presence of
peripheral pulses and reviewed the computed tomographic
angiogram. The site of arterial occlusions or stenoses
greater than 50% was documented from the angiogram,
and the peripheral vascular disease was recorded as aor-
toiliac, infrainguinal, or combined. ABPI measurements
were performed by a qualified sonographer. Participants
rested supine for 10 minutes before measurement of the
ABPI. The ABPI was calculated by measuring the systolic
blood pressure at the ankle (taking the highest of either the
dorsalis pedis or posterior tibial arteries) with a handheld
bidirectional Doppler scanner (MD6; D.E. Hokanson Inc.,
Bellevue, Wash, USA) and then dividing that value by the
systolic blood pressure in the brachial artery.22 Larger sphyg-
momanometer cuffs were used in obese patients. Treadmill
assessment was also performed. Patients were initially familiar-
ized with walking on the treadmill by a practice session.
Maximum walking distance (MWD) and initial claudication
distance (ICD) were subsequently measured during a graded
treadmill test.23 The treadmill test commenced at 3.2 km/h
and an incline of 0%, and the incline was increased by 2% every
2 minutes until voluntary exhaustion or maximal claudication
pain.24
Follow-up. Patients were followed up at 3, 6, 12, 18,
and 24 months. Notes were flagged to identify events
outside the review visits. The following end points were
noted: death, myocardial infarction, stroke, and coronary
or peripheral revascularization.
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sheet (Excel; Microsoft, Redmond, Wash) and transferred
to a statistical package for analysis (SPSS 12.0; SPSS Inc,
Chicago, Ill). Initially the relationships between waist cir-
cumference, waist-hip ratio, and circulating adipocytokines
and ABPI, ICD, and MWD were assessed. To investigate
the independent association of obesity and metabolic syn-
drome with the severity of intermittent claudication, mul-
tiple linear regression analysis was performed by using the
dependent variables ABPI, ICD, or MWD and the covari-
ants age, sex, smoking history, diabetes, hypertension, and
dyslipidemia (the last three criteria were not included in
metabolic syndrome analyses because these are part of the
diagnostic criteria). The influence of obesity or metabolic
syndrome on combined end points during follow-up was
assessed with Kaplan-Meier analysis. Because all events
occurred in patients with metabolic syndrome, we used a
surrogate marker of obesity—ie, waist circumference—to
perform a Cox proportional hazard analysis allowing for
other determinants of cardiovascular events (age, sex,
smoking, diabetes, hypertension, and dyslipidemia).
RESULTS
Characteristics of patients in relation to obesity and
metabolic syndrome. Between June 2003 and June
Table I. Characteristics of patients with intermittent claud
Variable Overall Present
n 60 48
Age (y) 67.3  7.8 68.40  7.4
Male 30 28
Current smoker 18 12
Ex-smoker 28 28
Nonsmoker 14 8
Diabetes mellitus 22 19
Hypertension 46 38
IHD 18 15
CVD 8 6
Waist circumference (cm) 94.71  13.97 99.55  10.
Waist-hip ratio 0.901  0.091 0.928  0.0
BMI (kg/m2) 28.37  4.39 29.86  3.2
% Fat 33.21  7.22 36.11  6.4
Cholesterol (mmol/L)* 4.99  1.12 4.97  1.1
Triglyceride (mmol/L)† 1.75  0.98 1.88  1.0
HDL (mmol/L)* 1.45  0.43 1.41  0.4
LDL (mmol/L)* 2.77  1.03 2.73  1.0
CRP (mg/L) 4.56  7.13 5.31  7.7
Lowest ABPI 0.61  0.14 0.58  0.1
MWD (m) 425.54  279.90 371.85  232
ICD (m) 219.71  214.20 182.67  186
Adiponectin (g/mL) 10.15  3.17 9.40  2.8
Leptin (ng/mL) 83.25  94.08 90.99  101
Resistin (ng/mL) 20.61  19.50 21.40  21.
IHD, Ischemic heart disease; CVD, cerebrovascular disease; BMI, body m
C-reactive protein; ABPI, ankle-brachial pressure index; MWD, maximum
Shown are numbers or mean  SD.
*To convert to mg/dL, multiply by 38.67.
†To convert to mg/dL, multiply by 88.57.2005, 60 patients were entered into the study, of whom 48were defined as obese and 44 as having metabolic syn-
drome. The characteristics of patients in relation to
whether they were obese or had metabolic syndrome are
illustrated in Table I.
Relationship between obesity or metabolic syn-
drome and severity of peripheral arterial disease.
Waist-hip ratio, but not waist circumference, was correlated
with the severity of peripheral arterial disease as assessed by
ABPI (r  0.41; P  .001; Fig, a), but not by MWD (r 
0.18; P .17) or ICD (r 0.21; P .10). The severity of
peripheral arterial disease by all three different defini-
tions was correlated with serum adiponectin concentra-
tions (Fig, b-d). Allowing for other known determinants
of atherosclerosis, obesity was independently associated
with the severity of lower limb artery disease (Table II).
Metabolic syndrome was associated with the severity of
intermittent claudication as defined by MWD only (stan-
dardized coefficient0.343; P .02), allowing for age,
sex, and smoking history. The adipocytokines adiponectin
and leptin were strongly associated with ABPI after adjust-
ment for traditional cardiovascular risk factors (Table III).
Serum adiponectin was also weakly independently associ-
ated with MWD (standardized coefficient  0.277; P 
.04) and ICD (standardized coefficient 0.292; P .03).
on in relation to obesity and metabolic syndrome
esity Metabolic syndrome
Absent Present Absent
12 44 16
63.00  8.34 68.70  7.67 63.50  7.20
2 28 2
6 12 6
0 28 0
6 4 10
3 19 3
8 34 12
3 15 3
2 6 2
75.32  10.23 100.87  9.41 77.75  9.80
0.795  0.084 0.939  0.064 0.798  0.072
22.40  3.27 30.17  3.19 23.43  3.36
30.11  6.82 34.10  7.40 30.78  6.27
5.07  0.99 4.94  1.20 5.13  0.87
1.23  0.51 1.96  1.04 1.18  0.46
1.58  0.30 1.39  0.46 1.61  0.27
2.94  1.04 2.69  1.07 2.99  0.91
1.63  1.68 5.59  8.07 1.78  1.69
0.70  0.08 0.58  0.14 0.67  0.08
640.24  356.11 373.44  237.19 568.79  342.08
367.87  261.04 190.30  191.57 300.57  256.40
13.14  2.86 9.71  2.73 11.37  4.00
52.28  48.60 87.95  105.03 70.32  54.32
17.46  8.57 21.92  22.15 17.00  8.39
dex; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP,
g distance; ICD, initial claudication distance.icati
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mum of 12 months unless they experienced a terminal
event. Three patients died 15, 21, and 22 months after
Fig. Scatterplots showing the relationship between waist
artery disease. Waist-hip ratio was correlated with ankle
Serum adiponectin was correlated with ABPI (b, r 0.3
P  .04), and initial claudication distance (ICD) (d, r 
Table II. Multiple regression models relating traditional r
PAD measure
ABPI
Standardized coefficient* P value Standa
Age 0.057 .70
Female sex 0.157 .30
Smoking 0.160 .31
Diabetes 0.364 .003
Hypertension 0.215 .09
Dyslipidemia 0.066 .58
Obesity 0.279 .03
PAD, Peripheral arterial disease; ABPI, ankle-brachial pressure index; ICD,
Overall model: ABPI, F  3.52, P  .004; ICD, F  2.35, P  .03; MWD
*Reduction in the severity of PAD per unit change in factor or compared wentry into the study. Although no autopsies were per-formed, the deaths were all believed to be secondary to
cardiac events. Twelve further cardiovascular events oc-
curred. Four patients had nonfatal myocardial infarctions,
atio or serum adiponectin and the severity of lower limb
hial pressure index (ABPI) (a, r  0.41; P  .001).
.01), maximum walking distance (MWD) (c, r 0.26;
; P  .005).
ctors and obesity to severity of peripheral arterial disease
ICD MWD
d coefficient* P value Standardized coefficient* P value
172 .28 0.003 .99
057 .72 0.203 .18
151 .36 0.346 .03
168 .19 0.169 .15
140 .29 0.228 .07
070 .58 0.028 .81
370 .009 0.435 .001
l claudication distance; MWD, maximum walking distance.
0.69, P  .003.
bjects without the factor.-hip r
-brac
1; Pisk fa
rdize
0.
0.
0.
0.
0.
0.
0.
initiaand one was treated by a coronary artery bypass graft. Three
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underwent a carotid endarterectomy. Two patients devel-
oped critical lower limb ischemia and required open arterial
reconstruction (aortic bypass and femoropopliteal bypass).
Three patients had deterioration of their intermittent clau-
dication and underwent peripheral revascularization. By
Kaplan-Meier analysis at 24 months, the incidence of car-
diovascular events was 37.2% 7.4% and 42.8% 9.1% in
patients with metabolic syndrome and obesity, respectively,
compared with 0% and 11.2%  6.1% in patients without
these diagnoses. Because no event occurred in patients
without metabolic syndrome, it was problematic to relate
obesity and metabolic syndrome independently to cardio-
vascular outcome. We therefore used waist circumference
as a continuous variable and performed Cox proportional
hazard analysis. Waist circumference was independently
associated with an increased risk of cardiovascular events
(Table IV).
DISCUSSION
The incidence of obesity is increasing, and there is now
greater focus on this risk factor as a cause of coronary artery
disease.1-6 Lower limb artery disease is present in approxi-
mately 10% of the population over 60 years old, but in
comparison with ischemic heart disease, it is poorly inves-
tigated.25 The importance of obesity in the development
Table III. Multiple regression model relating traditional
risk factors and adipocytokines to ABPI
Variable Standardized coefficient* P value
Age 0.293 .04
Female sex 0.303 .11
Smoking 0.202 .18
Diabetes 0.138 .24
Hypertension 0.128 .27
Dyslipidemia 0.037 .74
Adiponectin 0.506 .001
Leptin 0.589 .001
Resistin 0.101 .39
ABPI, Ankle-brachial pressure index.
Overall model: F  5.04; P  .001.
*Change in ABPI per unit change in factor or compared with subjects
without the factor.
Table IV. Predictors of outcome events
Variable Relative risk 95% CI P value
Age (per 1 y) 1.03 0.92-1.14 .62
Female sex 0.25 0.06-1.14 .07
Smoking 5.11 1.30-39.86 .02
Diabetes 5.64 1.36-23.38 .01
Hypertension 1.32 0.21-8.50 .77
Dyslipidemia 1.20 0.70-1.40 .99
Waist (per 1 cm) 1.16 1.08-1.26 .001
CI, Confidence interval.
Overall model: 2  32.4; P  .001.and progression of peripheral arterial disease has receivedrelatively little attention. The recent American task force
practice guidelines for the management of patients with
peripheral arterial disease did not consider obesity as a
treatable cause of lower limb artery disease.26 Some, but
not all, studies have correlated obesity with the presence of
lower limb artery disease, particularly when obesity is
defined by abdominal girth measurements.7-9,12-14,27,28
However, there are few investigations of how obesity af-
fects the severity and outcome of lower limb artery disease.
This study suggests the importance of obesity in pre-
dicting more severe lower limb artery disease and worse
outcomes during follow-up in patients with intermittent
claudication. Obesity independently predicted more severe
intermittent claudication as assessed by ABPI, ICD, or
MWD (Table II). Metabolic syndrome was associated only
with MWD. The most important finding of this study was
the poor outcome of patients with obesity or metabolic
syndrome during intermediate-term follow-up. All the pa-
tients who had a cardiovascular event during follow-up had
metabolic syndrome. Although as a result of this disparity it
was not possible to include metabolic syndrome in a Cox
proportional hazard analysis, we did assess the independent
association between waist circumference and outcome
events (Table IV). This analysis demonstrated an important
association between larger waist circumference and in-
creased outcome events.
The correlation between serum adiponectin and all
three measures of the severity of peripheral arterial disease
suggests that this adipocytokine plays an important role in
the poor prognosis associated with obesity in patients with
lower limb ischemia (Fig). Both adiponectin and leptin
were particularly associated with ABPI after adjustment for
other cardiovascular risk factors. Serum adiponectin levels
have been previously negatively correlated with coronary
artery disease severity and progression.29,30 Recently,
Iwashima and colleagues31 reported an association be-
tween ABPI and serum adiponectin, although the investi-
gators did not perform any functional tests of peripheral
arterial disease. In animal models, adiponectin has been
demonstrated to protect against the development of ath-
erosclerosis.32 Several mechanisms have been suggested for
this protective effect, including inhibition of thrombus
formation and inflammation.33-35
Interpretation of this study must take into account
several limitations. In developing this study,webelieved that it
was important to enter a homogenous group of patients—ie,
patients with intermittent claudication planned to be treated
conservatively. These tight entry criteria and the detailed
number of investigations performed restricted the sample
size. It will be important to confirm our findings in a larger
cohort. We also plan to extend the follow-up for this group
to assess whether the identified differences persist in the
long term.We defined outcome in this study in terms of the
clinical end points death, cardiovascular events, and revas-
cularization. Most events during follow-up (10/15) were
cardiovascular events. Five additional patients required re-
vascularization for the development of critical ischemia
(n  2) or worsening intermittent claudication (n  3).
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intermittent claudication can be influenced by factors un-
related to the progression of peripheral arterial disease: eg,
the type of arterial occlusive lesion. However, because most
outcome events in this study were unrelated to revascular-
ization for intermittent claudication, we do not believe that
these factors altered our results. Ideally, other measures of
outcome, such as health-related quality of life or objective
assessments of peripheral arterial disease, would have been
valuable to assess.36
In conclusion, the findings of this study suggest that
obesity and metabolic syndrome predict poor outcome for
patients with peripheral vascular disease. Interventions to
target this problem in patients with lower limb artery
disease are required.
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